Pruritus in hepatic cholestasis has been suggested to be secondary to a high concentration of serum bile acids. Rifampicin, which inhibits the uptake of bile acids by hepatocytes, has been used to treat pruritus. To determine the efficacy of rifampicin as a treatment for refractory pruritus, the medical records of 33 children (median age 25 months, range 4-135; 19 boys) with chronic cholestatic liver disease (21 with Alagille's syndrome, eight with progressive intrahepatic cholestasis, one with extrahepatic biliary atresia, one with an inborn error of bile acid metabolism, and one with cryptogenic cirrhosis) were reviewed restrospectively. The median dose of rifampicin was 5 (4-10) mg/kg/day. The median duration of intake was 36 (4-120) weeks.
Pruritus in hepatic cholestasis is a major disabling symptom which interferes with the daily activities and sleep of patients.' The mechanism ofpruritus is uncertain, though it is believed that the high concentration of bile acids causes hepatocyte membrane injury and triggers the release of pruritogenic substances. Several drugs have been used with variable success. The range of recommended treatment includes cholestyramine,2 phenobarbitone,3 ursodeoxycholic acid,4 androgenic steroids,5 naloxone,6 histamine antagonists,7 plasmapheresis,5 and phototherapy. In pruritus which is unresponsive to medical management, the partial external diversion of bile has been proposed for patients with progressive intrahepatic cholestasis. 9 Rifampicin, an antimicrobial drug widely used in the treatment of tuberculosis, has been shown to be effective against pruritus. Podesta et al have shown in a double blind placebo controlled study of 14 patients with primary biliary cirrhosis that the drug at 600 mg/day gave complete relief of pruritus in 11 (79%) and partial response in three (21%) patients. "' In a similar double blind crossover study in children with chronic cholestatic liver disease,'" rifampicin at 10 mg/kg/day was likewise shown to be effective in alleviating pruritus in all five patients.
The effect of treatment with rifampicin has been attributed to its ability to enhance the activity ofthe mixed function oxidase system and increasing the content of the hepatic cytochrome P-450.'2 These promote 6-a hydroxylation and subsequent 6-a glucoronidation of bile acids, thus decreasing the pool of toxic bile acids and facilitating the synthesis of protective acids.'3 It has also been suggested that because of its antimicrobial action, rifampicin modifies the synthesis of secondary bile acids in the intestinal lumen and consequently reduces the amount of hepatotoxic lithocolic bile acids.
At the paediatric liver service, King's College Hospital, rifampicin has been used to treat pruritus in children with hepatic cholestasis which was refractory to cholestyramine, phenobarbitone, ursodeoxycholic acid, antihistamines, or ultraviolet treatment. The objective of this study was to determine whether rifampicin was an effective treatment in these patients.
Patients and methods A retrospective analysis was made of the medical records of all 33 patients who were given rifampicin as a treatment for pruritus. The median age ofthe patients was 25 All patients had an alkaline phosphatase of >300 IU/1. Marked hypercholesterolaemia (>15 mmol/l) was shown in 10 of 30 (30%) patients, all of whom had Alagille's syndrome.
In the total series of patients no significant differences were noted in the laboratory parameters before and after one, three, and six months of rifampicin treatment. Among the 21 patients with Alagille's syndrome, however, a significant decrease in alkaline phosphatase was shown before and after one and six months of starting treatment with rifampicin (table 3) .
Complete relief of pruritus was noted in five (15%) patients whereas a partial response was shown in 12 (36%). No beneficial effect was seen in 16 (48%) patients. One of the drugs known to inhibit the uptake of bile acids by the hepatocyte is rifampicin.'3 The efficacy of rifampicin as a drug for the treatment of pruritus was first described by Ghent and Carruthers in a double blind, randomised crossover trial in nine patients with primary biliary cirrhosis who were all unresponsive to cholestyramine. 14 Rifampicin was given at a dose of 300-450 mg/day and the effect was evident after the first week of treatment. Bachs and Pares have likewise shown that rifampicin is more effective than phenobarbitone in alleviating pruritus associated with primary biliary cirrhosis.3
Effect ofrifampicin in pruritus Our study in 33 children with a variety of cholestatic liver diseases has shown that rifampicin at a median dose of 5 (4-10) mg/kg/day was successful in.17 (52%) patients in producing a complete or partial relief of pruritus. All these patients had intractable pruritus not relieved by other drugs such as cholestyramine, phenobarbitone, ursodeoxycholic acid, antihistamines, or ultraviolet treatment. In an earlier report, Cynamon et al showed that rifampicin was effective in the treatment of pruritus in 100% of patients." This study, however, used only five children, aged 1-17 years, diagnosed to have non-syndromic paucity of the intrahepatic bile ducts (two children), progressive intrahepatic cholestasis (two children), and extrahepatic biliary atresia (one child). In our series, the response was noted in 10 patients with Alagille's syndrome, three with progressive intrahepatic cholestasis, and one patient each with extrahepatic biliary atresia, giant cell hepatitis, inborn error of bile acid metabolism, and cryptogenic cirrhosis.
Although rifampicin has been shown to enhance the hepatic microsomal drug oxidising system leading to drug interactions when given simultaneously with phenobarbitone,'2 ursodeoxycholic acid, cholestyramine, or antihistamines, there was no significant difference in the response whether the patient was receiving rifampicin alone or on other drugs for the treatment of pruritus.
In the total series, there was no improvement in the biochemical indices before and after treatment with rifampicin. In the 21 patients with Alagille's syndrome, however, a significant decrease in alkaline phosphate was noted after one and six months oftreatment with rifampicin. This finding confirms a previous report by Bachs and Pares3 who also showed an improvement in alkaline phosphatase, in addition to the serum bile acids and y glutamyl transpeptidase levels after rifampicin treatment of patients with primary biliary cirrhosis. The effect has been attributed to the ability of rifampicin to induce microsomal activity. Although the drug has been shown to compete with the uptake of organic anions by the liver and impair biliary excretion, causing an increase in both unconjugated and conjugated forms of bilirubin,' 16 
